CALCIMEDICA INC
CALCNASDAQTrading Snapshot
- Day Range
- $1.20 – $1.33
- 52-Week Range
- $1.00 – $36.00
- Volume (shares)
- 91,265
- Avg Volume (shares)
- —
- Shares Outstanding
- 6.8M
- Next Earnings
- 2027-03-02
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.64
- Dividend Yield
- —
- Dilution (1yr)
- +17.6%
CALCIMEDICA INC
CALCAbout CALCIMEDICA INC
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

What Makes CalciMedica Inc. (CALC) a New Buy Stock
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027

CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC)

CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts
Shares of CalciMedica Inc. (NASDAQ: CALC - Get Free Report) have been assigned a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC)

CalciMedica Announces One-for-Five Reverse Stock Split
LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) c